Dr. Hilary Eaton is the Chief Business Officer at Profluent Bio, an AI-first protein design company initially focusing on gene editing. Dr. Eaton has more than a decade of experience in BD and strategy at leading gene editing companies, including Editas, Vor and Tome. Prior to her career in business development, she received her PhD from Duke University and completed a postdoc at Harvard Medical School / Dana-Farber Cancer Institute.